Novel Therapies for Sleep Apnea-The Implants Have Arrived
Positive airway pressure (PAP) therapy has been the standard treatment of choice for sleep disordered breathing, with 29-83% of patients being noncompliant. With the advent of newly Food and Drug Adminisatration (FDA)-approved implantable stimulators for treating sleep disordered breathing in a frac...
Saved in:
Published in | The Neurodiagnostic journal Vol. 58; no. 2; p. 116 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
03.04.2018
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Summary: | Positive airway pressure (PAP) therapy has been the standard treatment of choice for sleep disordered breathing, with 29-83% of patients being noncompliant. With the advent of newly Food and Drug Adminisatration (FDA)-approved implantable stimulators for treating sleep disordered breathing in a fraction of noncompliant PAP therapy patients, the landscape of sleep medicine and sleep technology is changing to narrow the gap between compliant and non-compliant patients. The remedē® System for treating central sleep apnea and the Inspire® upper airway stimulation (UAS) therapy for treating obstructive sleep apnea are providing new tools for sleep physicians, elevating sleep technologists' expertise, and paving the way for personalized medicine. |
---|---|
ISSN: | 2164-6821 |
DOI: | 10.1080/21646821.2018.1475805 |